&nbsp;

BigBackground3.jpg

Sep 2019

Document

DiscussingBiosimilarsPatientsProviderResource

Oct 2019

Document

Best Practice Guidance for Patient-Specific Quality Assurance (PSQA) for IMRT and VMAT Plan Delivery Verification

Nov 2019

Document

BiosimilarPatients.pdf

Nov 2019

Document

BiosimilarPatients-FR.pdf

Nov 2019

Regimen

BORTCYCDOXPRED+R

Cancer Type:

Hematologic

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

ODB - General Benefit

prednisone

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Bortezomib - Previously Untreated Transplant Ineligible Mantle Cell Lymphoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2023

Drug

dinutuximab

Other Name(s): Unituxin®

Quick Link(s): Drug Monograph

Jun 2023

Regimen

BINIENCO+CETU

Cancer Type:

Gastrointestinal,

Colorectal

Intent: Palliative

Drugs Used:

binimetinib (Unfunded),

encorafenib (Unfunded),

cetuximab (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Jul 2023

Regimen

DARO

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

darolutamide - For the treatment of high risk non-metastatic castration resistant prostate cancer (nmCRPC), based on criteria

Drugs Used:

darolutamide

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

BELA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Drugs Used:

belantamab mafodotin (Unfunded)

... Show more tags